Cargando…
Use of Clinical Pathway Simulation and Machine Learning to Identify Key Levers for Maximizing the Benefit of Intravenous Thrombolysis in Acute Stroke
Expert opinion is that about 20% of emergency stroke patients should receive thrombolysis. Currently, 11% to 12% of patients in England and Wales receive thrombolysis, ranging from 2% to 24% between hospitals. The aim of this study was to assess how much variation is due to differences in local pati...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389935/ https://www.ncbi.nlm.nih.gov/pubmed/35862194 http://dx.doi.org/10.1161/STROKEAHA.121.038454 |
_version_ | 1784770564256169984 |
---|---|
author | Allen, Michael James, Charlotte Frost, Julia Liabo, Kristin Pearn, Kerry Monks, Thomas Everson, Richard Stein, Ken James, Martin |
author_facet | Allen, Michael James, Charlotte Frost, Julia Liabo, Kristin Pearn, Kerry Monks, Thomas Everson, Richard Stein, Ken James, Martin |
author_sort | Allen, Michael |
collection | PubMed |
description | Expert opinion is that about 20% of emergency stroke patients should receive thrombolysis. Currently, 11% to 12% of patients in England and Wales receive thrombolysis, ranging from 2% to 24% between hospitals. The aim of this study was to assess how much variation is due to differences in local patient populations, and how much is due to differences in clinical decision-making and stroke pathway performance, while estimating a realistic target thrombolysis use. METHODS: Anonymised data for 246 676 emergency stroke admissions to 132 acute hospitals in England and Wales between 2016 and 2018 was obtained from the Sentinel Stroke National Audit Programme data. We used machine learning to learn decisions on who to give thrombolysis to at each hospital. We used clinical pathway simulation to model effects of changing pathway performance. Qualitative research was used to assess clinician attitudes to these methods. Three changes were modeled: (1) arrival-to-treatment in 30 minutes, (2) proportion of patients with determined stroke onset times set to at least the national upper quartile, (3) thrombolysis decisions made based on majority vote of a benchmark set of hospitals. RESULTS: Of the modeled changes, any single change was predicted to increase national thrombolysis use from 11.6% to between 12.3% to 14.5% (clinical decision-making having the most effect). Combined, these changes would be expected to increase thrombolysis to 18.3%, but there would still be significant variation between hospitals depending on local patient population. Clinicians engaged well with the modeling, but those from hospitals with lower thrombolysis use were most cautious about the methods. CONCLUSIONS: Machine learning and clinical pathway simulation may be applied at scale to national stroke audit data, allowing extended use and analysis of audit data. Stroke thrombolysis rates of at least 18% look achievable in England and Wales, but each hospital should have its own target. |
format | Online Article Text |
id | pubmed-9389935 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-93899352022-08-19 Use of Clinical Pathway Simulation and Machine Learning to Identify Key Levers for Maximizing the Benefit of Intravenous Thrombolysis in Acute Stroke Allen, Michael James, Charlotte Frost, Julia Liabo, Kristin Pearn, Kerry Monks, Thomas Everson, Richard Stein, Ken James, Martin Stroke Original Contributions Expert opinion is that about 20% of emergency stroke patients should receive thrombolysis. Currently, 11% to 12% of patients in England and Wales receive thrombolysis, ranging from 2% to 24% between hospitals. The aim of this study was to assess how much variation is due to differences in local patient populations, and how much is due to differences in clinical decision-making and stroke pathway performance, while estimating a realistic target thrombolysis use. METHODS: Anonymised data for 246 676 emergency stroke admissions to 132 acute hospitals in England and Wales between 2016 and 2018 was obtained from the Sentinel Stroke National Audit Programme data. We used machine learning to learn decisions on who to give thrombolysis to at each hospital. We used clinical pathway simulation to model effects of changing pathway performance. Qualitative research was used to assess clinician attitudes to these methods. Three changes were modeled: (1) arrival-to-treatment in 30 minutes, (2) proportion of patients with determined stroke onset times set to at least the national upper quartile, (3) thrombolysis decisions made based on majority vote of a benchmark set of hospitals. RESULTS: Of the modeled changes, any single change was predicted to increase national thrombolysis use from 11.6% to between 12.3% to 14.5% (clinical decision-making having the most effect). Combined, these changes would be expected to increase thrombolysis to 18.3%, but there would still be significant variation between hospitals depending on local patient population. Clinicians engaged well with the modeling, but those from hospitals with lower thrombolysis use were most cautious about the methods. CONCLUSIONS: Machine learning and clinical pathway simulation may be applied at scale to national stroke audit data, allowing extended use and analysis of audit data. Stroke thrombolysis rates of at least 18% look achievable in England and Wales, but each hospital should have its own target. Lippincott Williams & Wilkins 2022-07-15 2022-09 /pmc/articles/PMC9389935/ /pubmed/35862194 http://dx.doi.org/10.1161/STROKEAHA.121.038454 Text en © 2022 The Authors. https://creativecommons.org/licenses/by/4.0/Stroke is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited. This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections. |
spellingShingle | Original Contributions Allen, Michael James, Charlotte Frost, Julia Liabo, Kristin Pearn, Kerry Monks, Thomas Everson, Richard Stein, Ken James, Martin Use of Clinical Pathway Simulation and Machine Learning to Identify Key Levers for Maximizing the Benefit of Intravenous Thrombolysis in Acute Stroke |
title | Use of Clinical Pathway Simulation and Machine Learning to Identify Key Levers for Maximizing the Benefit of Intravenous Thrombolysis in Acute Stroke |
title_full | Use of Clinical Pathway Simulation and Machine Learning to Identify Key Levers for Maximizing the Benefit of Intravenous Thrombolysis in Acute Stroke |
title_fullStr | Use of Clinical Pathway Simulation and Machine Learning to Identify Key Levers for Maximizing the Benefit of Intravenous Thrombolysis in Acute Stroke |
title_full_unstemmed | Use of Clinical Pathway Simulation and Machine Learning to Identify Key Levers for Maximizing the Benefit of Intravenous Thrombolysis in Acute Stroke |
title_short | Use of Clinical Pathway Simulation and Machine Learning to Identify Key Levers for Maximizing the Benefit of Intravenous Thrombolysis in Acute Stroke |
title_sort | use of clinical pathway simulation and machine learning to identify key levers for maximizing the benefit of intravenous thrombolysis in acute stroke |
topic | Original Contributions |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389935/ https://www.ncbi.nlm.nih.gov/pubmed/35862194 http://dx.doi.org/10.1161/STROKEAHA.121.038454 |
work_keys_str_mv | AT allenmichael useofclinicalpathwaysimulationandmachinelearningtoidentifykeyleversformaximizingthebenefitofintravenousthrombolysisinacutestroke AT jamescharlotte useofclinicalpathwaysimulationandmachinelearningtoidentifykeyleversformaximizingthebenefitofintravenousthrombolysisinacutestroke AT frostjulia useofclinicalpathwaysimulationandmachinelearningtoidentifykeyleversformaximizingthebenefitofintravenousthrombolysisinacutestroke AT liabokristin useofclinicalpathwaysimulationandmachinelearningtoidentifykeyleversformaximizingthebenefitofintravenousthrombolysisinacutestroke AT pearnkerry useofclinicalpathwaysimulationandmachinelearningtoidentifykeyleversformaximizingthebenefitofintravenousthrombolysisinacutestroke AT monksthomas useofclinicalpathwaysimulationandmachinelearningtoidentifykeyleversformaximizingthebenefitofintravenousthrombolysisinacutestroke AT eversonrichard useofclinicalpathwaysimulationandmachinelearningtoidentifykeyleversformaximizingthebenefitofintravenousthrombolysisinacutestroke AT steinken useofclinicalpathwaysimulationandmachinelearningtoidentifykeyleversformaximizingthebenefitofintravenousthrombolysisinacutestroke AT jamesmartin useofclinicalpathwaysimulationandmachinelearningtoidentifykeyleversformaximizingthebenefitofintravenousthrombolysisinacutestroke |